We are monitoring the impact of COVID-19 on Europe Pancreatic Cancer Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1205
Share on
Share on

Europe Pancreatic Cancer Market Research Report – Segmented By Treatment Type, Cancer Type, End Users & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends & Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1205
Pages: 179

Europe Pancreatic Cancer Market Size (2021 to 2026)

The size of the Pancreatic Cancer Market in Europe was worth USD 0.63 billion in 2021 and is estimated to be growing at a CAGR of 6.98 %, to reach USD 0.88 billion by 2026.

Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The occurrence and mortality rate of pancreatic cancer is more in men than in women. Pancreatic cancer is currently the 4th leading cause of death by cancer in Europe. And it is expected to become 2nd by 2020.

Pancreatic cancer starts when cells in the pancreas start to grow incessantly eventually resulting in symptoms like abdominal pain, weight loss, diarrhea, and jaundice.  The developed tumor hinders the normal functioning of the pancreas. The biggest risk factor which leads to pancreatic cancer is smoking. Apart from lifestyle-dependent factors like alcohol consumption, obesity, and smoking, a personal or family history of pancreatitis or old age may result in a person being affected by pancreatic cancer. Pancreatic cancer patients lose 98% of their healthy life expectancy at the point of diagnosis itself.

Pancreatic cancer mortality rates are increasing in many countries across the continent, and it is estimated it will cause 91,500 deaths next year. Clearly, this is also the most challenging aspect that this market needs to address. Given the insuppressible nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of the majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.

This research report on the European Pancreatic Cancer Market is segmented & sub-segmented into the following categories:

By Treatment Type:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Others

By Cancer Type:

  • Exocrine Pancreas Cancer
  • Endocrine Pancreas Cancer

By End User:

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Notable companies leading the European pancreatic cancer market profiled in this report are Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.  

1.Introduction          

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions                

2. Research Methodology                   

                2.1 Introduction      

                2.2 Research Phases                      

        2.2.1 Secondary Research            

        2.2.2 Primary Research 

        2.2.3 Econometric Modelling     

        2.2.4 Expert Validation  

                2.3 Analysis Design 

                2.4 Study Timeline  

3. Overview              

                3.1 Executive Summary                

                3.2 Key Inferences 

                3.3 Epidemology     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)              

                4.1 Market Drivers  

                4.2 Market Restraints                    

                4.3 Key Challenges 

                4.4 Current Opportunities in the Market               

5. Market Segmentation                      

                5.1 Type of Treatment                  

        5.1.1 Introduction           

        5.1.2 Surgery    

        5.1.3 Chemotherapy     

        5.1.4 Radiation Therapy

        5.1.5 Others      

        5.1.6 Y-o-Y Growth Analysis, By Type of Treatment          

        5.1.7 Market Attractiveness Analysis, By Type of Treatment         

        5.1.8 Market Share Analysis, By Type of Treatment          

                5.2 Type      

        5.2.1 Introduction           

        5.2.2 Exocrine Pancreas Cancer

        5.2.3 Endocrine Pancreas Cancer              

        5.2.4 Y-o-Y Growth Analysis, By Type      

        5.2.5 Market Attractiveness Analysis, By Type     

        5.2.6 Market Share Analysis, By Type      

                5.3 End-users                   

        5.3.1 Introduction           

        5.3.2 Hospitals  

        5.3.3 Clinics        

        5.3.4 Research Institutes             

        5.3.5 Others      

        5.3.6 Y-o-Y Growth Analysis, By End-users            

        5.3.7 Market Attractiveness Analysis, By End-users          

        5.3.8 Market Share Analysis, By End-users           

6. Geographical Analysis                      

                6.1 Introduction      

        6.1.1 Regional Trends    

        6.1.2 Impact Analysis     

        6.1.3 Y-o-Y Growth Analysis        

                        6.1.3.1 By Geographical Area

                        6.1.3.2 By Type of Treatment

                        6.1.3.3 By Type

                        6.1.3.4 By End-users

        6.1.4 Market Attractiveness Analysis      

                        6.1.4.1 By Geographical Area

                        6.1.4.2 By Type of Treatment

                        6.1.4.3 By Type

                        6.1.4.4 By End-users

        6.1.5 Market Share Analysis        

                        6.1.5.1 By Geographical Area

                        6.1.5.2 By Type of Treatment

                        6.1.5.3 By Type

                        6.1.5.4 By End-users

                6.2 U.K                

                6.3 Spain     

                6.4 Germany                     

                6.5 Italy       

                6.6 France  

7.Strategic Analysis                

                7.1 PESTLE analysis 

        7.1.1 Political     

        7.1.2 Economic 

        7.1.3 Social         

        7.1.4 Technological         

        7.1.5 Legal          

        7.1.6 Environmental      

                7.2 Porter’s Five analysis      

        7.2.1 Bargaining Power of Suppliers        

        7.2.2 Bargaining Power of Consumers    

        7.2.3 Threat of New Entrants     

        7.2.4 Threat of Substitute Products and Services

        7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                  

                8.1 Eli Lilly   

        8.1.1 Overview

        8.1.2 Type of Product    

        8.1.3 Financial analysis  

        8.1.4 Recent Developments       

        8.1.5 SWOT analysis       

        8.1.6 Analyst View          

                8.2 Amgen, Inc.                

                8.3 Celgene Corp.   

                8.4 F. Hoffmann-La Roche   

                8.5 Clovis Oncology Inc.                

                8.6 Pfizer    

                8.7 Novartis AG                

                8.8 Threshold Pharmaceuticals Inc.  

                8.9 Aduro BioTech Inc.                  

                8.10 Infinity Pharmaceuticals Inc.     

                8.11 NewLink Genetics Corp.                      

9.Competitive Landscape                    

                9.1 Market share analysis    

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, collaborations and Joint Ventures  

                9.4 New Product Launches  

10.Market Outlook and Investment Opportunities                   

Appendix                   

                a) List of Tables                

                b) List of Figures      

 

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  2. Europe Surgery Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Radiation Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  7. Europe Exocrine Pancreas Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Endocrine Pancreas Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)
  10. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Research Institutes Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  14. U.K. Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  15. U.K. Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  16. U.K. Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)
  17. Germany Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  18. Germany Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  19. Germany Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)
  20. France Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  21. France Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  22. France Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)
  23. Italy Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  24. Italy Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  25. Italy Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)
  26. Spain Pancreatic Cancer Market, By Type of Treatment, From 2021 to 2026 (USD Billion)
  27. Spain Pancreatic Cancer Market, By Type, From 2021 to 2026 (USD Billion)
  28. Spain Pancreatic Cancer Market, By End-users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample